Latest Breaking News On - Gabriel morris - Page 6 : vimarsana.com

Immix Biopharma, Inc : Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U S Patient Dosing

Immix Biopharma, Inc : Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U S Patient Dosing
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesRheinland pfalzMike moyerGabriel morrisIlya rachmanClinical cancer researchImmix biopharma incDrug administrationMeeting of the european society for bloodAmerican society of hematologyExchange commissionView researchNexcella incAmerican society for geneInternational myeloma societyCompany contact

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U S Patient Dosing

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

United statesIlya rachmanGabriel morrisAmerican society of hematologyMeeting of the european society for bloodView researchImmix biopharma incClinical cancer researchInternational myeloma societyDrug administrationAmerican society for geneImmix biopharmaInvestigational new drugChief executive officerAmerican societyAnnual meeting

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapyUpdated results will be communicated at the presentation time December 10,.

United statesSan diegoGrand viewLos angelesGabriel morrisMike moyerIlya rachmanAmerican society of hematologyInternational myeloma working groupExchange commissionView researchCompany contactNexcella incImmix biopharma incAmerican societyAnnual meeting

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSan diego convention centerIlya rachmanMike moyerLos angelesGabriel morrisAmerican society of hematologyNexcella incInternational myeloma working groupImmix biopharma incExchange commissionAmerican societyAnnual meetingChief executive officerChief financial officer

Immix Biopharma (IMMX) to present additional NXC-201 clinical data at ASH

Immix Biopharma (IMMX) to present additional NXC-201 clinical data at ASH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoIlya rachmanGabriel morrisImmix biopharma incAmerican society of hematologyImmix biopharmaAmerican societyAnnual meetingChief executive officerChief financial officerNovel academicAntigen receptort cellPacific timeFrom light chainNovel diagnostics